NewsBenzingaLexeo Therapeutics公布其正在进行的LX2020用于治疗PKP2致心律失常性心肌病的HEROIC-PKP2 I/II期临床试验中期数据;在10名受试者中,包括9名至少随访12个月的受试者,LX2020治疗总体耐受性良好 Lexeo Therapeutics公布其正在进行的LX2020用于治疗PKP2致心律失常性心肌病的HEROIC-PKP2 I/II期临床试验中期数据;在10名受试者中,包括9名至少随访12个月的受试者,LX2020治疗总体耐受性良好 Benzinga 2026.11.16 12:07 (GMT+0) Open on Benzinga Other news Nvidia’s $105 Billion OpenAI Bet Has a 20-Year Catch Freedom Broker Upgrades Espey Manufacturing to Buy, Maintains Price Target to $70 QUICK SPARK: Chip Stocks Eye Worst Two-Month Drop Since 2008 Carlyle, Clearlake Bet Big On Sports — And PE Deals Are Surging Target's $301 Million Tariff Windfall 'Flattered' Earnings, Analyst Says Freedom Broker Maintains Buy on SKYX Platforms, Lowers Price Target to $2